Chapter 712: In Kyushu

After conducting as many experiments as possible in Jiuzhou, under the premise that policies allowed it.

Zheng Qian sent another group of researchers to Oman.

After arrangements were made by Rahman, they were responsible for the final control test preparations, which meant putting the Autonomous Driving System on the road in the true sense. This was different from closed test tracks; it was real feedback under commercial and civilian conditions.

They needed to perform as well as possible on various roads in Oman, and ideally, encounter all kinds of extreme road conditions.

Only then would it be possible to demonstrate the exaggerated learning and performance capabilities of the "Kuafu Model."

This set of experimental data would be used for the final paper in the Autonomous Driving series.

This matter would also come to a temporary close.

Zheng Qian went directly to the Chunshen Pharmaceutical Affiliated Hospital today.

As mentioned before, this was the Chunshen Pharmaceutical University Affiliated Hospital sponsored by the Ran Family, and the predecessor of this university was the Shanghu Medical University. Ran Gaopeng, who had been thrown down by Jin Lu, was currently here and remained in a comatose state.

Of course, Zheng Qian did not come here to see him.

"Brother-in-law, you are here so early."

Ran Gaolan from the Fourth Branch personally received him at the entrance.

The control of this hospital appeared to be with Chunshen Pharmaceutical University on the surface, but in reality, it was controlled by The Group's Ranren Pharmaceutical Group. Ran Gaolan was the president of Ranren Pharmaceutical Group, his father, Ran Tianhan, was the CEO, and his mother... was named Ran Yutai.

His father was not a son-in-law living with the wife's family; he was the eldest biological son of the Fourth Branch, and his mother was a distant cousin.

Therefore, because of their union, they were highly criticized and discriminated against within the Ran Family.

Also, due to their weak position, they had always clung tightly to Ran Xiang and President Ran Ruhuan, and now naturally, they firmly stood on Jin Lu's side.

"How are the experiments going?"

"Very successful. Currently, it is a 100% success rate, it is just... the number of patients is too small."

"Brother-in-law, you know, cholecystitis and appendicitis are very common minor surgeries. Even if we make it free for patients and offer a very high 'surgical participation fee,' people are not very trusting of this. The key is that the surgery itself is already very cheap."

Ran Gaolan introduced this to Zheng Qian as they walked, shaking his head and smiling bitterly.

The story starts a month ago.

Zheng Qian simultaneously launched two major plans. One was the Autonomous Driving System, which was the "Kuafu Model" that was now beginning to show its potential. The other was the medical model that would truly be used for the competition; this was the real trump card.

Currently, the actual role of AI in the medical field is not very high.

Apart from the "Ocular Disease Model" recently published in the journal "Science," the most eye-catching achievement was performing "autonomous laparoscopic surgery" on a pig. It was said that the surgery was very successful, and it was a surgery performed entirely by machines.

But in reality, an AI that performs surgery on humans completely autonomously has not yet appeared.

As for the appendicitis surgery...

This was, of course, not Zheng Qian's ultimate goal.

Even if this surgery were performed entirely by machines without human doctors operating, it would not shock the world that much. After all, very precise laparoscopic surgeries had already been performed on pigs, and something like appendicitis really held no challenge.

"Hmm, the basic situation is predictable. As long as the non-disclosure agreements are signed, it will be fine."

Zheng Qian pondered for a moment, his expression somewhat grave. "How is this surgery... being arranged? The little girl is quite pitiful. If possible, I would like to meet her and hear the opinions of her guardian and herself regarding this surgery."

Ran Gaolan nodded and signaled for Zheng Qian to follow him to the special care ward.

The ranking of Chunshen Pharmaceutical Affiliated Hospital is not high.

Whether it was its own research capabilities or its ability to provide high-level medical and health services to the surrounding area, it was not top-tier. Especially in an international metropolis like Shanghu, its strength was actually very limited; it had only barely managed to earn the title of a Grade-A tertiary hospital.

It was certainly fine for curing general illnesses, but some very complex tumors were difficult to overcome.

That is why "flying knives" are used at times like this.

Renowned doctors and masters in various fields would be invited here to perform the surgeries themselves.

Anyway, the Ran Family had deep financial resources. Plus, patients usually had to pay the "flying knife" fees, and since this was a private institution, the charges were relatively high. The hospital's profitability had always been decent, quite standard.

Then again, the Ran Family's industries appeared to be laid out in a complex and chaotic manner, with its subsidiaries scattered and disorganized.

In fact, the structure was very clear.

During the time when Jin Lu's mother, Ran Changxi, was in charge.

She integrated and divided the Ran Family's business into four major areas: Real Estate, Electronics, Life Sciences, and Finance.

The real estate and electronics companies developed the best, while the life Sciences and finance sectors were not very prominent. But that was only relative; compared to average private enterprises, they were already considered very good, which is why they could be maintained until now.

Furthermore, if this hospital were truly very strong, Ran Xiang would not have needed to go all the way to the United States for treatment.

The products of Ranren Pharmaceutical Group covered all categories, including cough suppressants, fever reducers, antibiotics, and antiviral drugs. In terms of traditional Chinese medicine, the company's "Glucose-Lowering Jiebai Pill" was suitable for diabetes and systemic syndromes caused by diabetes, and it was considered their best-selling drug.

It possessed a certain level of research and development capability, and because it was their own industry, the confidentiality was strong.

That was why Zheng Qian set the experimental work for this medical model here.

Arriving at the special care ward and looking at the haggard-looking girl, Zheng Qian sighed slightly in his heart.

The girl's name was Tiantian.

Even though this was not some famous hospital in Jiuzhou, the Ran Family had been deeply involved in this field for many years, and their connections could not be underestimated. Upon learning that Zheng Qian wanted to secretly challenge a bone marrow transplant surgery, they had sent people to keep an eye on many hospitals.

The costs here were very high, and with no top domestic experts presiding, people lacking money would not choose this place.

And those who chose this place naturally did not lack money; what they valued was the high-quality service of a private hospital.

They would just invite top experts to perform the surgery when the time came.

Tiantian was only 9 years old this year and was in the third grade of elementary school.

Her family was in very difficult circumstances, and paying the monthly expenses cost quite a lot of money.

Not to mention undergoing a surgery like a bone marrow transplant.

Under the doctor's recommendation, Tiantian was sent here.

If there had really been no other way, her parents would not have sent Tiantian here. Not to mention places far away, Shanghu alone had three top-tier hospitals ranked among the best in the country, with Ruixin Hospital being a standout, and treating leukemia was not difficult there.

But, Zheng Qian was offering simply too much.

And the promises were also very well-made.

Of course, it required the consent of the patient's family. As long as they accepted the AI surgery, regardless of the final outcome, they would receive a "participation fee" of 100 million USD. Most importantly, Zheng Qian promised to find top doctors from across the country to provide a safety net.

This meant that during the machine surgery process, if any problems arose, renowned doctors and masters would step in.

Furthermore, the entire surgery needed to be "televised live."

It was not a live stream on typical internet platforms, but rather recorded entirely by cameras, with patient families, renowned doctors, industry authorities, and even notary office staff witnessing it together to ensure every detail could be seen.

More importantly, it needed to be filed and approved.

In a sense, this was no longer just a "new surgical procedure."

If such an important and complex surgery were carried out without authorization, it would be fine if it succeeded, but if it failed, it would involve many issues in various aspects. It was not just a matter of handling the patient's family; it also involved many legal and ethical issues.

The reason it had been delayed until now to start the surgery was precisely to prepare for these matters.

Fortunately, it was unclear if it was because Zheng Qian had played ball with that "Boss."

The approval process was faster than imagined.

The "Boss" had expressed that they should encourage the innovative spirit of researchers. On the basis of ensuring the success rate of the surgery, a considerable degree of cooperation should be provided. After repeated verification, they must strive for the safety of the surgical process.

Today, the expert consultation room was gathered with top doctors from Jiuzhou.

Including but not limited to: Academician Sun Zhongming, President of Shanghu Ruixin Hospital; Academician Fang, Vice President of Shanghu Changshan Affiliated Hospital; Professor Chang from Zhongnan Xiangyuan Hospital... and others. They were all waiting for the birth of the world's first artificial intelligence bone marrow transplant surgery.

Actually, if Zheng Qian had conducted the surgery in Oman.

There would be far fewer policy restrictions, and he would not need to worry too much about the series of subsequent problems that might arise.

As long as Rahman nodded, he could easily arrange anything Zheng Qian needed.

But, if that were the case, it would be the first artificial intelligence bone marrow transplant completed "in Oman."

And not "in Jiuzhou."

Every aspect had withstood tremendous pressure.

All for this moment.

And the surgery was about to begin today.